Additional file 1: Supplemental Figure 1. Local site and systemic adverse reactions in 44 patients with multiple myeloma within 7 days of dose 1 and dose 2 of the SARS-CoV-2 mRNA vaccine. Supplemental Table 1. Anti-SARS-CoV-2 RBD antibody titer of 44 patients multiple myeloma 1 month after two-dose SARS-CoV-2 mRNA vaccination by demographics and clinical characteristics.